Topic starter
18/11/2025 3:27 pm
On October 31, 2025, the Ministry of Health issued a special authorization allowing the distribution of Pembroria, a Russian formulation containing Pembrolizumab, one of the world’s most effective immunotherapy agents.
The drug, produced by Russia’s LLC PK-137 and imported through a UAE-based distributor, will be available in 100 mg/4 ml vials for intravenous infusion.